Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supernus Aims For IPO Backed By Unusual Royalty Deal

This article was originally published in Start Up

Executive Summary

CNS-focused Supernus Pharmaceuticals Inc. filed its intent to go public just before Christmas, making it the last biopharma to file in a year that ended with some cautious optimism about the IPO market. But Supernus stands apart from the year’s success stories in that most of its $157 million in financing in five years of existence has been non-dilutive. Thus, even if the company trims its offer price, investors are poised for a satisfying payoff.

You may also be interested in...



Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech

Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.

US Biopharma IPOs: Market's Rally Passes Them By

Continuing the trend from 2010, biopharma initial public offerings in 2011 are running into stubborn resistance from public investors, a frustrating development as markets otherwise soar to pre-recession levels. More often than not, drug companies are squeezing through the IPO window, which reopened in late 2009, by selling more shares at lower prices. The discounts mean companies raise less cash, and they strain beleaguered venture investors who must hold shares longer to reach an attractive exit price.

Baked-In Goodness: Shire Buys New River for $2.6 Billion

Shire's $2.6 billion all-cash acquisition of its Vyvanse partner New River Pharmaceuticals is no surprise. The original deal signed by the companies in 2005 engineered Shire's motivation to buy New River in the event Vyvanse became a success. New River's unusually consolidated ownership allowed it to remain independent until the eve of Vyvanse's approval and secure a top-drawer takeout valuation.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS100968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel